Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study-Reference-Cited by-同舟云学术

Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study

Published:2021-08-13 Issue:1 Volume:41 Page:123-127
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Egeli Bugra Han,Ergun Sercan,Cetin Arya,Gursoy Yahya Kerem,Ugurlu Serdal^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-021-05871-9.pdf

Reference21 articles.

1. Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372(18):1734–1747

2. Drake LA, Dinehart SM, Farmer ER et al (1996) Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 34(5 Pt 1):824–829

3. Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28(6):913–921

4. Henriksson KG, Sandstedt P (1982) Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand 65(4):280–300

5. Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review;Autoimmunity Reviews;2023-02

2. Rituximab in myositis: where are we now? A survey of current usage;Rheumatology;2023-01-09

3. Off-Label Uses of Rituximab in Dermatology;Current Dermatology Reports;2022-10-06